Opportunity Information: Apply for PAR 25 055
The NIH funding opportunity PAR-25-055, titled "Clinical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U01 Clinical Trial Optional)," is a cooperative agreement designed to move promising neurological and neuromuscular biomarkers from the "we think this works" stage to the "this is clinically reliable" stage. The core aim is not discovery of new biomarkers or early assay development, but rigorous clinical validation of an already well-supported candidate biomarker in the intended patient population. In practical terms, the program is trying to generate the kind of evidence that would stand up to regulatory expectations, including FDA-aligned performance metrics, by establishing how well the biomarker predicts what it is supposed to predict in real clinical settings.
A central emphasis of the announcement is measuring clinical predictive performance, specifically positive predictive value (PPV) and negative predictive value (NPV), within the clinical population where the biomarker is meant to be used. That focus signals that applications should be designed around real-world decision contexts, where prevalence, patient selection, and disease heterogeneity strongly influence PPV and NPV. The opportunity is essentially asking applicants to design studies that can credibly answer questions like: when the biomarker result is positive, how likely is it that the patient truly has (or will develop, worsen, respond, etc.) the condition of interest; and when the result is negative, how confident can clinicians be that the condition is absent (or that progression/response will not occur) within the defined context of use. The intent is to produce evidence that supports clinical confidence and potential downstream qualification or adoption pathways.
The program also makes clear assumptions about readiness. To be responsive, a project should already have (1) a clearly identified candidate biomarker with strong preliminary support, (2) a detection method or assay technology that has been developed and analytically validated, and (3) a defined clinical or research need along with an articulated potential "context of use" for the biomarker. In other words, the biomarker and its measurement approach should be past the exploratory phase. The work proposed under this PAR should concentrate on validating the biomarker measurement in the relevant patient population, rather than building the assay from scratch, optimizing basic detection chemistry, or performing open-ended discovery studies.
The funding mechanism is a U01 cooperative agreement, which typically means there is substantial NIH involvement during the project compared with a standard investigator-initiated grant. Applicants should expect collaborative stewardship, milestone-driven oversight, and an expectation that study design, performance benchmarks, and data quality practices will be strong enough to support broad confidence in the findings. The notice also states "Clinical Trial Optional," meaning the proposed work may include a clinical trial if it is necessary for validation, but a trial is not mandatory; well-designed observational or prospective cohort validation studies may be appropriate depending on the biomarker and intended use.
Eligibility is broad across public and private sectors, reflecting NIH's goal of attracting capable teams wherever they are based. Eligible applicants include state, county, and local governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; and Native American tribal organizations that are not federally recognized. Nonprofits are eligible whether or not they have 501(c)(3) status, and both for-profit organizations (other than small businesses) and small businesses may apply. The announcement explicitly highlights additional eligible applicant types such as Alaska Native and Native Hawaiian Serving Institutions, AANAPISIS institutions, Hispanic-serving institutions, Historically Black Colleges and Universities, Tribally Controlled Colleges and Universities, faith-based or community-based organizations, regional organizations, eligible federal agencies, and U.S. territories or possessions.
At the same time, the geographic rules are specific: non-domestic (non-U.S.) entities (foreign organizations) are not eligible to apply, and non-domestic components of U.S. organizations are not eligible to apply. However, foreign components as defined by the NIH Grants Policy Statement are allowed, which generally means a U.S.-based applicant can include certain international elements (for example, specific collaborations or performance sites) if they meet NIH policy requirements and are justified scientifically, but the applicant organization itself must be U.S.-based.
From the administrative details provided, the sponsoring agency is the National Institutes of Health, the opportunity category is discretionary, and the activity category is health under CFDA 93.853. The opportunity was created on 2024-10-02, and the original closing date listed is 2026-06-22. The award ceiling and expected number of awards are not specified in the provided extract, which usually means applicants need to consult the full announcement and any linked institute-specific guidance to understand budget expectations, project period norms, and how many awards might be anticipated.
Overall, PAR-25-055 is best understood as a translational validation bridge: it is aimed at teams who already have a strong biomarker candidate and a working, analytically validated measurement method, and who now need to prove, in the real clinical population and with FDA-consistent rigor, that the biomarker meaningfully predicts clinically relevant states or outcomes within a clearly defined context of use. The deliverable NIH is pushing for is high-quality evidence of performance (including PPV and NPV) that can support confident clinical interpretation and future regulatory or clinical implementation steps.Apply for PAR 25 055
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Clinical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U01 Clinical Trial Optional)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.853.
- This funding opportunity was created on 2024-10-02.
- Applicants must submit their applications by 2026-06-22. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs) - NIH PAR-25-055
What is PAR-25-055?
PAR-25-055 is an NIH funding opportunity titled "Clinical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U01 Clinical Trial Optional)." It supports rigorous clinical validation of an already well-supported candidate biomarker in its intended patient population, with an emphasis on generating evidence that is credible in real clinical settings and aligned with regulatory expectations.
What is the main goal of this funding opportunity?
The main goal is to move a promising neurological or neuromuscular biomarker from preliminary promise to clinically reliable performance by validating how well it predicts clinically relevant states or outcomes in the real population where it would be used. The program is focused on clinical validation, not biomarker discovery.
Is this opportunity for discovering new biomarkers?
No. The opportunity is not intended for discovery of new biomarkers or open-ended exploratory studies. It is designed for projects that already have a clearly identified candidate biomarker with strong preliminary support and are ready for rigorous clinical validation in the intended use population.
What kinds of disorders does this opportunity target?
The opportunity targets biomarkers related to neurological or neuromuscular disorders. The provided information does not list specific diseases, but the intent is clearly within neurology and neuromuscular clinical contexts.
What does "clinical validation" mean in the context of PAR-25-055?
Clinical validation here means demonstrating, in the relevant patient population and real-world decision context, that the biomarker reliably predicts what it is intended to predict (for example, presence of disease, risk of developing a condition, likelihood of progression, or response). The emphasis is on evidence that can support clinical confidence and potential downstream regulatory or adoption pathways.
What performance metrics are emphasized in this announcement?
A central emphasis is on clinical predictive performance, specifically positive predictive value (PPV) and negative predictive value (NPV), measured in the clinical population where the biomarker is intended to be used.
Why does PAR-25-055 emphasize PPV and NPV?
Because PPV and NPV reflect how a biomarker result performs in the actual clinical context of use, where prevalence, patient selection, and disease heterogeneity can strongly influence what a positive or negative result truly means for decision-making.
What types of clinical questions should a validation study be able to answer?
The program is looking for studies that can credibly answer questions such as: if the biomarker result is positive, how likely is it that the patient truly has (or will develop, worsen, or respond in the way of interest); and if the result is negative, how confident can clinicians be that the condition is absent (or that progression/response will not occur) within a defined context of use.
What level of readiness is expected for the biomarker and assay?
To be responsive, a project is expected to already have: (1) a clearly identified candidate biomarker with strong preliminary support, (2) a detection method or assay technology that has been developed and analytically validated, and (3) a defined clinical or research need with an articulated potential context of use. The work proposed should focus on validating performance in the relevant patient population, not building or inventing the assay.
Is early assay development or assay optimization supported?
The emphasis is not on early assay development or optimizing basic detection chemistry. The program assumes the assay technology has already been developed and analytically validated, and that the next step is rigorous clinical validation in the intended population.
What is meant by a "defined context of use"?
A defined context of use means a clear statement of how and where the biomarker is intended to be used (for example, in which clinical population and decision context) and what it is intended to predict. The opportunity expects applicants to articulate this context and design validation studies around it.
What funding mechanism is used for PAR-25-055?
The mechanism is a U01 cooperative agreement. This typically involves substantial NIH involvement compared with a standard investigator-initiated grant.
What does NIH involvement look like under a U01 cooperative agreement?
Based on the provided information, applicants should expect collaborative stewardship, milestone-driven oversight, and expectations for strong study design, performance benchmarks, and data quality practices to support broad confidence in the findings.
Does the project have to include a clinical trial?
No. The announcement is "Clinical Trial Optional." A clinical trial may be included if needed for validation, but it is not mandatory. Well-designed observational or prospective cohort validation studies may be appropriate depending on the biomarker and intended use.
What kinds of study designs might be appropriate under this opportunity?
The opportunity allows flexibility: projects may include a clinical trial if necessary, or may use observational or prospective cohort validation designs, as long as the design is rigorous and supports credible estimation of clinical predictive performance (including PPV and NPV) in the intended population and context of use.
Who is eligible to apply?
Eligibility is broad and includes state, county, and local governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; and non-federally recognized Native American tribal organizations. Nonprofits (with or without 501(c)(3) status), for-profit organizations (other than small businesses), and small businesses may also apply.
Are there specific institution types explicitly highlighted as eligible?
Yes. The announcement explicitly highlights eligibility for Alaska Native and Native Hawaiian Serving Institutions, AANAPISIS institutions, Hispanic-serving institutions, Historically Black Colleges and Universities, Tribally Controlled Colleges and Universities, faith-based or community-based organizations, regional organizations, eligible federal agencies, and U.S. territories or possessions.
Can foreign (non-U.S.) organizations apply?
No. Non-domestic (non-U.S.) entities (foreign organizations) are not eligible to apply.
Can a U.S. organization include non-U.S. components?
Non-domestic components of U.S. organizations are not eligible to apply. However, foreign components (as defined by the NIH Grants Policy Statement) are allowed, which generally means a U.S.-based applicant may include certain international elements if they meet NIH policy requirements and are scientifically justified.
What is the sponsoring agency and opportunity category?
The sponsoring agency is the National Institutes of Health (NIH). The opportunity category is discretionary.
What is the activity category and CFDA number listed?
The activity category is health, under CFDA 93.853.
When was this opportunity created and what is the listed closing date?
The opportunity was created on 2024-10-02. The original closing date listed is 2026-06-22.
Is there an award ceiling or expected number of awards stated in the provided information?
No. The award ceiling and expected number of awards are not specified in the provided extract. Applicants would typically need to consult the full announcement and any linked institute-specific guidance for budget expectations, project period norms, and anticipated number of awards.
What is the overall "fit" for a team considering applying?
This opportunity is aimed at teams that already have a strong biomarker candidate and an analytically validated measurement method, and that now need to prove clinical reliability in the real intended patient population. The expected deliverable is high-quality evidence of clinical predictive performance (including PPV and NPV) suitable to support confident clinical interpretation and potential future regulatory or clinical implementation steps.
Browse more opportunities from the same category: Health
Next opportunity: Request for Information (RFI) Plant Genetic Engineering for Energy Applications
Previous opportunity: Organs-on-a-Chip in Dental, Oral, and Craniofacial Research (DOC-OoCs) (R01 Clinical Trial Not Allowed)
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 25 055
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 25 055) also looked into and applied for these:
| Funding Opportunity |
|---|
| Research Experiences and/or Mentoring Networks through Research Education to Enhance Clinician-Scientists' Participation in NIDCDs Research (R25 Clinical Trial Not Allowed) Apply for PAR 25 020 Funding Number: PAR 25 020 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| Analytical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders(U01 Clinical Trial Optional) Apply for PAR 25 050 Funding Number: PAR 25 050 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Limited Competition: CCRP Initiative: Promoting a Basic Understanding of Chemical Threats to Skin (R34 Clinical Trial Not Allowed) Apply for PA 25 093 Funding Number: PA 25 093 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Centers on the Demography and Economics of Aging and Alzheimers Disease and Alzheimers Disease-Related Dementias Coordinating Center (U24 Clinical Trial Optional) Apply for RFA AG 25 008 Funding Number: RFA AG 25 008 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Centers for Precision Disease Modeling (U54) (Clinical Trials Not Allowed) Apply for PAR 24 305 Funding Number: PAR 24 305 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Development of Alternative Human Models of Radiation-Induced Injuries (Extracorporeal Systems) (U01 Clinical Trial Not Allowed) Apply for RFA AI 24 067 Funding Number: RFA AI 24 067 Agency: National Institutes of Health Category: Health Funding Amount: $350,000 |
| Centers on the Demography and Economics of Aging, Including Alzheimer's Disease and Alzheimer's Disease-Related Dementias (AD/ADRD) (D and E Centers) (P30 Clinical Trial Optional) Apply for RFA AG 25 007 Funding Number: RFA AG 25 007 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Ryan White HIV/AIDS Program Part C Early Intervention Services Program: Limited Existing Geographic Service Areas Apply for HRSA 25 052 Funding Number: HRSA 25 052 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| National Rural Health Information Clearinghouse Program Apply for HRSA 25 009 Funding Number: HRSA 25 009 Agency: Health Resources and Services Administration Category: Health Funding Amount: $3,500,000 |
| State Offices of Rural Health Coordination and Development Program (SORHCDP) Apply for HRSA 25 034 Funding Number: HRSA 25 034 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Occupational Safety and Health Education and Research Centers (T42) Apply for RFA OH 25 002 Funding Number: RFA OH 25 002 Agency: Centers for Disease Control and Prevention - ERA Category: Health Funding Amount: $9,000,000 |
| USAID Access Miahy Apply for 72068724RFA00007 Funding Number: 72068724RFA00007 Agency: Madagascar USAID-Antananarivo Category: Health Funding Amount: $90,000,000 |
| Advancing Community Health Activity (ACHA) Apply for 72066924RFA00002 Funding Number: 72066924RFA00002 Agency: Liberia USAID-Monrovia Category: Health Funding Amount: $23,000,000 |
| USAID Access Miahy Apply for 72068724RFA00008 Funding Number: 72068724RFA00008 Agency: Madagascar USAID-Antananarivo Category: Health Funding Amount: $90,000,000 |
| USAID Primary Health Care Improvement Program (UPHIP) Apply for 72062024RFA00009 Funding Number: 72062024RFA00009 Agency: Nigeria USAID-Abuja Category: Health Funding Amount: $40,000,000 |
| Continuation or Revision of NIDCR Clinical Trial Planning and Implementation Cooperative Agreement (UH3 Clinical Trial Required) Apply for PAR 25 062 Funding Number: PAR 25 062 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| New Therapeutic Strategies for Genital Herpes (R21/R33 Clinical Trial Not Allowed) Apply for RFA AI 24 068 Funding Number: RFA AI 24 068 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Data Coordinating Center for NCCIH Multi-Site Investigator-Initiated Clinical Trials of Mind and Body Interventions (Collaborative U24 Clinical Trial Required) Apply for PAR 24 276 Funding Number: PAR 24 276 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Building Biomedical Engineering Education, Research, and Innovation at Historically Black Colleges and Universities (HBCU eBETA) (UG3/UH3 Clinical Trial Not Allowed) Apply for RFA EB 25 002 Funding Number: RFA EB 25 002 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Mental Health and Psychosocial Support (MHPSS) Program in Ethiopia Apply for 72066325RFI00001 Funding Number: 72066325RFI00001 Agency: Ethiopia USAID-Addis Ababa Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 25 055", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.